At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 43 enrolled
Drug / intervention
Genotropin (PN-180,307) Somatropin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two Year Multicentre, Randomized Two Arm Study Of Genotropin Treatment In Very Young Children Born Small For Gestational Age: Early Growth And Neurodevelopment(Egn)
In Brief
A Phase 3 clinical trial evaluating Genotropin (PN-180,307) Somatropin and Control-no treatment for Infant, Small for Gestational Age. Completed, enrolled 43 participants across 17 sites in 9 countries.
Detailed Summary
To demonstrate the effect on height and psychomotor development of Growth Hormone treatment in very young children starting at an age of 2 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfant, Small for Gestational Age
CountriesBelgium, Czechia, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedMar 2008
Primary CompletionDec 2013
TodayJul 2026
First PostedMar 3, 2008
Enrollment StartFeb 1, 2008
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.3 years ago
Interventions
Genotropin (PN-180,307) Somatropindrug
Injectable Genotropin
Control-no treatmentdrug
Control-no treatment